Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Maria Gonzalez-Angulo

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|September 21, 2014
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBCHong Zhou, Khalid A Mohamedali, Ana Maria Gonzalez-Angulo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2021
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast CancerArgun Akcakanat, Xiaofeng Zheng, Christian X Cruz Pico, et al.
Annals of Diagnostic Pathology|September 11, 2014
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancerJane H Zhou, Daniel Rosen, Andreas Andreou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomesShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitorsFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging systemMin Yi, Elizabeth A Mittendorf, Janice N Cormier, et al.
EMBO Molecular Medicine|December 17, 2011
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancerYun-Yong Park, Kyounghyun Kim, Sang-Bae Kim, et al.
The Journal of Experimental Medicine|March 21, 2012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionDai Horiuchi, Leonard Kusdra, Noelle E Huskey, et al.
Cancer Research|August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after ChemotherapyRussell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Breast Cancer Research : BCR|June 24, 2010
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton, Xiaoyong Fu, Bryan T Hennessy, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|September 21, 2014
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBCHong Zhou, Khalid A Mohamedali, Ana Maria Gonzalez-Angulo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2021
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast CancerArgun Akcakanat, Xiaofeng Zheng, Christian X Cruz Pico, et al.
Annals of Diagnostic Pathology|September 11, 2014
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancerJane H Zhou, Daniel Rosen, Andreas Andreou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomesShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitorsFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging systemMin Yi, Elizabeth A Mittendorf, Janice N Cormier, et al.
EMBO Molecular Medicine|December 17, 2011
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancerYun-Yong Park, Kyounghyun Kim, Sang-Bae Kim, et al.
The Journal of Experimental Medicine|March 21, 2012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionDai Horiuchi, Leonard Kusdra, Noelle E Huskey, et al.
Cancer Research|August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after ChemotherapyRussell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Breast Cancer Research : BCR|June 24, 2010
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton, Xiaoyong Fu, Bryan T Hennessy, et al.
Pageof 8